SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Price, Forecast & Analysis
USA - NASDAQ:SUPN - US8684591089 - Common Stock
SUPN Key Statistics, Chart & Performance
The current stock price of SUPN is 44.9 USD. In the past month the price decreased by -11.39%. In the past year, price increased by 23.96%.
SUPN Latest News, Press Relases and Analysis
SUPN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.84 | 974.90B | ||
| JNJ | JOHNSON & JOHNSON | 19.27 | 481.67B | ||
| MRK | MERCK & CO. INC. | 10.95 | 240.86B | ||
| PFE | PFIZER INC | 7.95 | 144.70B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.17 | 95.79B | ||
| ZTS | ZOETIS INC | 18.63 | 52.36B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.6 | 23.01B | ||
| VTRS | VIATRIS INC | 4.6 | 12.49B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.28 | 10.63B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.35 | 7.91B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.36B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.30B |
Related stock screener links
About SUPN
Company Profile
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 674 full-time employees. The company went IPO on 2010-12-28. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. The company also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
Company Info
SUPERNUS PHARMACEUTICALS INC
9715 Key West Avenue
Rockville MARYLAND 20850 US
CEO: JACK A. KHATTAR
Employees: 674
Phone: 13018382500
SUPERNUS PHARMACEUTICALS INC / SUPN FAQ
Can you describe the business of SUPERNUS PHARMACEUTICALS INC?
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 674 full-time employees. The company went IPO on 2010-12-28. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. The company also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
Can you provide the latest stock price for SUPERNUS PHARMACEUTICALS INC?
The current stock price of SUPN is 44.9 USD. The price decreased by -0.42% in the last trading session.
Does SUPN stock pay dividends?
SUPN does not pay a dividend.
What is the ChartMill technical and fundamental rating of SUPN stock?
SUPN has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the analyst forecast for SUPN stock?
12 analysts have analysed SUPN and the average price target is 59.36 USD. This implies a price increase of 32.21% is expected in the next year compared to the current price of 44.9.
What is the Price/Earnings (PE) ratio of SUPERNUS PHARMACEUTICALS INC (SUPN)?
The PE ratio for SUPERNUS PHARMACEUTICALS INC (SUPN) is 14.48. This is based on the reported non-GAAP earnings per share of 3.1 and the current share price of 44.9 USD.
Who owns SUPERNUS PHARMACEUTICALS INC?
You can find the ownership structure of SUPERNUS PHARMACEUTICALS INC (SUPN) on the Ownership tab.
SUPN Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SUPN. When comparing the yearly performance of all stocks, SUPN is one of the better performing stocks in the market, outperforming 80.53% of all stocks.
SUPN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to SUPN. SUPN has only an average score on both its financial health and profitability.
SUPN Financial Highlights
Over the last trailing twelve months SUPN reported a non-GAAP Earnings per Share(EPS) of 3.1. The EPS increased by 0.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| Debt/Equity | 0 |
SUPN Forecast & Estimates
12 analysts have analysed SUPN and the average price target is 59.36 USD. This implies a price increase of 32.21% is expected in the next year compared to the current price of 44.9.
For the next year, analysts expect an EPS growth of -8.49% and a revenue growth 9.29% for SUPN